Schering-Plough, Incyte Report Positive Mid-Stage Data For CCR5 Antagonists
This article was originally published in The Pink Sheet Daily
Executive Summary
Both Schering’s vicriviroc and Incyte’s INCB9471 CCR5 antagonist candidates to treat HIV beat placebo in Phase II trials.